MA53126B1 - Agents de dégradation sélectifs du récepteur des oestrogènes - Google Patents

Agents de dégradation sélectifs du récepteur des oestrogènes

Info

Publication number
MA53126B1
MA53126B1 MA53126A MA53126A MA53126B1 MA 53126 B1 MA53126 B1 MA 53126B1 MA 53126 A MA53126 A MA 53126A MA 53126 A MA53126 A MA 53126A MA 53126 B1 MA53126 B1 MA 53126B1
Authority
MA
Morocco
Prior art keywords
estrogen receptor
selective estrogen
receptor degraders
degraders
serd
Prior art date
Application number
MA53126A
Other languages
English (en)
Other versions
MA53126A (fr
Inventor
Jeffrey Daniel Cohen
Daniel Jon Sall
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53126(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from PCT/US2019/041342 external-priority patent/WO2020014440A1/fr
Publication of MA53126A publication Critical patent/MA53126A/fr
Publication of MA53126B1 publication Critical patent/MA53126B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

L'invention concerne de nouveaux agents de dégradation sélectifs du récepteur des oestrogènes (serd) selon la formule , des sels pharmaceutiquement acceptables, des compositions pharmaceutiques, des utilisations et des procédés d'utilisation de ceux-ci.
MA53126A 2018-07-12 2019-07-11 Agents de dégradation sélectifs du récepteur des oestrogènes MA53126B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
PCT/US2019/041342 WO2020014440A1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs du récepteur des oestrogènes

Publications (2)

Publication Number Publication Date
MA53126A MA53126A (fr) 2021-05-19
MA53126B1 true MA53126B1 (fr) 2023-02-28

Family

ID=67470734

Family Applications (2)

Application Number Title Priority Date Filing Date
MA53126A MA53126B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs du récepteur des oestrogènes
MA53124A MA53124B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA53124A MA53124B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes

Country Status (37)

Country Link
US (4) US10654866B2 (fr)
EP (2) EP4155310A1 (fr)
JP (6) JP6995241B2 (fr)
KR (3) KR102589886B1 (fr)
CN (2) CN117379428A (fr)
AR (3) AR115694A1 (fr)
AU (2) AU2019299947B2 (fr)
BR (1) BR122023025061A2 (fr)
CA (1) CA3105501C (fr)
CL (1) CL2021000045A1 (fr)
CO (1) CO2021000043A2 (fr)
CR (1) CR20210007A (fr)
DK (1) DK3820873T3 (fr)
EA (1) EA202092975A1 (fr)
EC (1) ECSP21001770A (fr)
ES (1) ES2933980T3 (fr)
FI (2) FI3820873T3 (fr)
HR (1) HRP20230009T1 (fr)
HU (1) HUE060963T2 (fr)
IL (3) IL289871B2 (fr)
JO (1) JOP20210005B1 (fr)
LT (1) LT3820873T (fr)
MA (2) MA53126B1 (fr)
MD (1) MD3820873T2 (fr)
MX (2) MX2021000375A (fr)
MY (1) MY198962A (fr)
PE (1) PE20210400A1 (fr)
PH (1) PH12021550049A1 (fr)
PL (1) PL3820873T3 (fr)
PT (1) PT3820873T (fr)
RS (1) RS63809B1 (fr)
SA (1) SA521421008B1 (fr)
SG (1) SG11202100148TA (fr)
SI (1) SI3820873T1 (fr)
TW (1) TWI702219B (fr)
UA (1) UA127507C2 (fr)
WO (1) WO2020014435A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
CA3144791A1 (fr) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimes d'antagonistes du recepteur des oestrogenes
JP7680438B2 (ja) 2019-10-01 2025-05-20 サノフイ 新規の置換６，７－ジヒドロ－５ｈ－ベンゾ［７］アンヌレン化合物、その製造方法およびその治療的使用
BR112022009705A2 (pt) 2019-12-09 2022-08-09 Sanofi Sa Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
AU2021366223A1 (en) 2020-10-19 2023-06-22 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
US12595230B2 (en) 2020-10-19 2026-04-07 Sanofi Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
IL303041A (en) * 2020-11-23 2023-07-01 Sanofi Sa Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
KR20230146523A (ko) * 2021-02-16 2023-10-19 제넨테크, 인크. Gdc-9545 및 아베마시클립 또는 리보시클립을 포함하는병용 요법을 사용한 유방암 치료
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TWI894443B (zh) * 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
KR102743629B1 (ko) * 2022-02-01 2024-12-17 일라이 릴리 앤드 캄파니 선택적 에스트로겐 수용체 분해제의 제조 방법
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
CN120051280A (zh) 2022-10-17 2025-05-27 阿斯利康(瑞典)有限公司 用于治疗癌症的serd的组合
KR20250105413A (ko) 2022-11-02 2025-07-08 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
WO2024100236A1 (fr) 2022-11-11 2024-05-16 Astrazeneca Ab Polythérapies pour le traitement du cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
KR20260005985A (ko) 2023-05-05 2026-01-12 일라이 릴리 앤드 캄파니 Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염
KR20260010420A (ko) 2023-05-11 2026-01-20 아스트라제네카 아베 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
WO2002094788A1 (fr) * 2001-05-22 2002-11-28 Eli Lilly And Company 1,2,3,4-tetrahydroquinoline 2-substituees et leurs derives, ainsi que leurs composition et leurs procedes
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
WO2003086394A1 (fr) * 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibiteurs de l'activite akt
EP1497277A1 (fr) * 2002-04-19 2005-01-19 Signal Pharmaceuticals, Inc. Composes benzopyranone, compositions contenant ces composes et methodes de traitement associees
AU2005207821B2 (en) 2004-01-22 2011-02-10 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
MX2015016171A (es) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
CN117865872A (zh) * 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
WO2017127442A1 (fr) * 2016-01-18 2017-07-27 The Regents Of The University Of California Méthodes de traitement du cancer à l'aide d'inhibiteurs ror gamma
US10125135B2 (en) * 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
WO2018108954A1 (fr) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Procédé de préparation de 2-(3-(fluorométhyl)azétidin-1-yl)éthan-1-ol
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
IL280065A (en) 2021-03-01
IL280065B (en) 2022-04-01
FIC20260010I1 (fi) 2026-04-07
JP7241211B2 (ja) 2023-03-16
CR20210007A (es) 2021-02-08
MA53124B1 (fr) 2023-02-28
WO2020014435A1 (fr) 2020-01-16
JP7746496B2 (ja) 2025-09-30
US11117902B2 (en) 2021-09-14
SA521421008B1 (ar) 2022-10-30
SI3820873T1 (sl) 2023-02-28
NZ771718A (en) 2024-05-31
US11634426B2 (en) 2023-04-25
EA202092975A1 (ru) 2021-04-14
US20200347073A1 (en) 2020-11-05
JP2021530484A (ja) 2021-11-11
US10654866B2 (en) 2020-05-19
IL289871B2 (en) 2023-02-01
US20230234960A1 (en) 2023-07-27
JP2025186400A (ja) 2025-12-23
CA3105501C (fr) 2023-10-31
MA53124A (fr) 2021-05-19
MX2023006047A (es) 2023-06-02
US11993608B2 (en) 2024-05-28
KR102589886B1 (ko) 2023-10-17
UA127507C2 (uk) 2023-09-13
BR112020025654A2 (pt) 2021-04-06
EP4155310A1 (fr) 2023-03-29
EP3820873A1 (fr) 2021-05-19
PL3820873T3 (pl) 2023-02-13
FI3820873T3 (fi) 2023-03-02
KR20230148386A (ko) 2023-10-24
US20210403480A1 (en) 2021-12-30
JOP20210005A1 (ar) 2021-01-10
IL289871A (en) 2022-03-01
AU2022203969B2 (en) 2024-02-15
HUE060963T2 (hu) 2023-04-28
KR102550538B1 (ko) 2023-07-04
DK3820873T3 (da) 2022-12-12
JP2023081954A (ja) 2023-06-13
IL295598A (en) 2022-10-01
CO2021000043A2 (es) 2021-01-18
KR20230005404A (ko) 2023-01-09
AU2019299947A1 (en) 2021-01-07
AR134662A2 (es) 2026-03-04
PT3820873T (pt) 2022-12-23
CL2021000045A1 (es) 2021-07-19
CA3105501A1 (fr) 2020-01-16
AR134487A2 (es) 2026-01-21
AR115694A1 (es) 2021-02-17
JP2022050591A (ja) 2022-03-30
US20200017516A1 (en) 2020-01-16
JP7557564B2 (ja) 2024-09-27
JP2022037102A (ja) 2022-03-08
CN117379428A (zh) 2024-01-12
MX2021000375A (es) 2021-05-27
HRP20230009T1 (hr) 2023-02-17
BR122023025061A2 (pt) 2024-02-20
RS63809B1 (sr) 2023-01-31
EP3820873B1 (fr) 2022-11-23
AU2022203969A1 (en) 2022-06-30
CN112638916A (zh) 2021-04-09
ES2933980T3 (es) 2023-02-15
IL295598B1 (en) 2023-05-01
MA53126A (fr) 2021-05-19
TWI702219B (zh) 2020-08-21
MD3820873T2 (ro) 2023-05-31
IL289871B (en) 2022-10-01
JP6995241B2 (ja) 2022-01-14
CN112638916B (zh) 2023-09-12
KR20210019065A (ko) 2021-02-19
JP7009672B1 (ja) 2022-01-25
MY198962A (en) 2023-10-05
PH12021550049A1 (en) 2021-09-20
JP2024169490A (ja) 2024-12-05
SG11202100148TA (en) 2021-02-25
AU2019299947B2 (en) 2022-03-17
JOP20210005B1 (ar) 2023-03-28
TW202019935A (zh) 2020-06-01
PE20210400A1 (es) 2021-03-02
LT3820873T (lt) 2023-01-10
IL295598B2 (en) 2023-09-01
ECSP21001770A (es) 2021-02-26
KR102783756B1 (ko) 2025-03-21

Similar Documents

Publication Publication Date Title
MA53124B1 (fr) Agents de dégradation sélectifs des récepteurs des oestrogènes
MA58498B1 (fr) Agonistes hétérocycliques de glp-1
EP4685160A3 (fr) Polythérapie comprenant un inhibiteur de krasg12c et un ou plusieurs agents pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MA40225A (fr) Composés dihydroisoquinolinone substitués
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
EA202192553A1 (ru) Protac, расщепляющие рецептор эстрогена
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
MA65149A1 (fr) Formes cristallines à l'état solide d'un modulateur sélectif du canal potassique
MA34760B1 (fr) Composés et leurs utilisation
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
UA96277C2 (en) Benzimidazole derivatives
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
MA34746B1 (fr) Dérivés de diphénylamine : utilisations, procédés de synthèse et compositions pharmaceutiques
NO20044473L (no) Ikke-steroidal progesteron reseptor modulatorer